Compounds repurposed to promote remyelination in MS currently in phase III clinical trials, such as clemastine and thyroid hormone analogs23,55,87, generate OLs at the expense of OPCs, thus potentially depleting OPCs in the long term. This evidence concerns the gene TG and myeloid sarcoma.